Adc Therapeutics Sa Stock Analysis
| ADCT Stock | USD 3.91 0.18 4.40% |
IPO Date 16th of March 1979 | 200 Day MA 3.2748 | 50 Day MA 3.7776 | Beta 1.954 |
ADC Therapeutics holds a debt-to-equity ratio of 2.755. Net Debt To EBITDA is likely to gain to 1.65 in 2026, whereas Net Debt is likely to drop (154.4 M) in 2026. ADC Therapeutics' financial risk is the risk to ADC Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
ADC Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. ADC Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps ADC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect ADC Therapeutics' stakeholders.
For many companies, including ADC Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for ADC Therapeutics SA, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, ADC Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 2.5787 | Enterprise Value Ebitda (1.43) | Price Sales 6.4237 | Shares Float 110 M | Wall Street Target Price 8 |
ADC Therapeutics SA is undervalued with Real Value of 4.89 and Target Price of 8.0. The main objective of ADC Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what ADC Therapeutics SA is worth, separate from its market price. There are two main types of ADC Therapeutics' stock analysis: fundamental analysis and technical analysis.
The ADC Therapeutics stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ADC Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. ADC Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADC Therapeutics SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. ADC Stock Analysis Notes
About 14.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.74. ADC Therapeutics recorded a loss per share of 1.41. The entity had not issued any dividends in recent years. ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. ADC Therapeutics operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 312 people. For more info on ADC Therapeutics SA please contact Christopher Martin at 41 21 653 02 00 or go to https://www.adctherapeutics.com.ADC Therapeutics Investment Alerts
| ADC Therapeutics had very high historical volatility over the last 90 days | |
| ADC Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 70.84 M. Net Loss for the year was (157.85 M) with loss before overhead, payroll, taxes, and interest of (43.18 M). | |
| ADC Therapeutics SA currently holds about 376.78 M in cash with (123.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ADC Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Redmile Group, Llc of 144517 shares of ADC Therapeutics at 3.5872 subject to Rule 16b-3 |
ADC Largest EPS Surprises
Earnings surprises can significantly impact ADC Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.38 | -0.42 | -0.04 | 10 | ||
2025-05-05 | 2025-03-31 | -0.4143 | -0.36 | 0.0543 | 13 | ||
2023-05-09 | 2023-03-31 | -0.67 | -0.74 | -0.07 | 10 |
ADC Therapeutics Environmental, Social, and Governance (ESG) Scores
ADC Therapeutics' ESG score is a quantitative measure that evaluates ADC Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of ADC Therapeutics' operations that may have significant financial implications and affect ADC Therapeutics' stock price as well as guide investors towards more socially responsible investments.
ADC Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-06-30 | 1.2 M | Geode Capital Management, Llc | 2025-06-30 | 858.8 K | Woodline Partners Lp | 2025-06-30 | 842.9 K | Ubs Group Ag | 2025-06-30 | 827.6 K | Blue Owl Capital Holdings Lp | 2025-06-30 | 733.6 K | Vantage Consulting Group Inc. | 2025-06-30 | 683 K | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 597.8 K | Vanguard Group Inc | 2025-06-30 | 560.5 K | Northern Trust Corp | 2025-06-30 | 426.9 K | Redmile Group, Llc | 2025-06-30 | 15.7 M | Prosight Management, Lp | 2025-06-30 | 10.5 M |
ADC Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 483.12 M.ADC Profitablity
The company has Profit Margin (PM) of (2.22) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.86) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.86.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.49) | (0.51) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | 0.70 | 0.74 |
Management Efficiency
ADC Therapeutics has return on total asset (ROA) of (0.2398) % which means that it has lost $0.2398 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0553) %, meaning that it created substantial loss on money invested by shareholders. ADC Therapeutics' management efficiency ratios could be used to measure how well ADC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.74 in 2026, whereas Return On Tangible Assets are likely to drop (0.46) in 2026. At this time, ADC Therapeutics' Non Current Liabilities Total is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 3.4 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 51 M in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.40) | (2.28) | |
| Tangible Book Value Per Share | (2.40) | (2.28) | |
| Enterprise Value Over EBITDA | (0.57) | (0.60) | |
| Price Book Value Ratio | (1.10) | (1.04) | |
| Enterprise Value Multiple | (0.57) | (0.60) | |
| Price Fair Value | (1.10) | (1.04) | |
| Enterprise Value | 75.3 M | 71.5 M |
ADC Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Technical Drivers
As of the 5th of February, ADC Therapeutics owns the variance of 22.13, and Market Risk Adjusted Performance of (0.06). ADC Therapeutics SA technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.ADC Therapeutics Price Movement Analysis
The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Moving Average is predictive technique used to analyze ADC Therapeutics price data points by creating a series of averages of different subsets of ADC Therapeutics entire price series.
ADC Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADC Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADC Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ADC Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ADC Therapeutics Outstanding Bonds
ADC Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ADC Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ADC bonds can be classified according to their maturity, which is the date when ADC Therapeutics SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
ADC Therapeutics Predictive Daily Indicators
ADC Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ADC Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 54634.58 | |||
| Daily Balance Of Power | (0.58) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 4.04 | |||
| Day Typical Price | 3.99 | |||
| Price Action Indicator | (0.21) | |||
| Period Momentum Indicator | (0.18) |
ADC Therapeutics Forecast Models
ADC Therapeutics' time-series forecasting models are one of many ADC Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ADC Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.ADC Therapeutics Bond Ratings
ADC Therapeutics SA financial ratings play a critical role in determining how much ADC Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for ADC Therapeutics' borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (1.42) | Possible Manipulator | View |
ADC Therapeutics Debt to Cash Allocation
ADC Therapeutics SA currently holds 123 M in liabilities with Debt to Equity (D/E) ratio of 2.76, implying the company greatly relies on financing operations through barrowing. ADC Therapeutics has a current ratio of 5.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ADC Therapeutics' use of debt, we should always consider it together with its cash and equity.ADC Therapeutics Total Assets Over Time
ADC Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which ADC Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.ADC Therapeutics Debt Ratio | 20.0 |
ADC Therapeutics Corporate Bonds Issued
ADC Net Debt
Net Debt |
|
About ADC Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ADC Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ADC shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ADC Therapeutics. By using and applying ADC Stock analysis, traders can create a robust methodology for identifying ADC entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (2.00) | (2.10) | |
| Operating Profit Margin | (1.66) | (1.74) | |
| Net Loss | (2.01) | (2.11) | |
| Gross Profit Margin | 0.82 | 0.87 |
Current ADC Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ADC analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ADC analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 8.0 | Strong Buy | 6 | Odds |
Most ADC analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ADC stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ADC Therapeutics, talking to its executives and customers, or listening to ADC conference calls.
ADC Stock Analysis Indicators
ADC Therapeutics SA stock analysis indicators help investors evaluate how ADC Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ADC Therapeutics shares will generate the highest return on investment. By understating and applying ADC Therapeutics stock analysis, traders can identify ADC Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 278.6 M | |
| Long Term Debt | 113.6 M | |
| Common Stock Shares Outstanding | 97.2 M | |
| Total Stockholder Equity | -202.6 M | |
| Total Cashflows From Investing Activities | -867 K | |
| Tax Provision | 166 K | |
| Property Plant And Equipment Net | 13.4 M | |
| Cash And Short Term Investments | 250.9 M | |
| Cash | 250.9 M | |
| Accounts Payable | 18 M | |
| Net Debt | -127.9 M | |
| 50 Day M A | 3.7776 | |
| Total Current Liabilities | 80.5 M | |
| Other Operating Expenses | 201.5 M | |
| Non Current Assets Total | 14.6 M | |
| Non Currrent Assets Other | 1.2 M | |
| Stock Based Compensation | 6.6 M |
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.